Drug Profile
IRX 5183
Alternative Names: AGN 195183; IRX5183; NRX 195183; VTP-195183Latest Information Update: 07 Jan 2023
Price :
$50
*
At a glance
- Originator Allergan
- Developer Io Therapeutics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Class Antineoplastics; Antipsoriatics
- Mechanism of Action Immunostimulants; Retinoic acid receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Cancer
- No development reported Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Discontinued Psoriasis; Stem cell mobilisation
Most Recent Events
- 26 Dec 2022 IRX 5183 is still in phase I trials for Acute myeloid leukaemia (Second-line therapy or greater), Chronic myelomonocytic leukaemia (Second-line therapy or greater), Myelodysplastic syndromes (Second-line therapy or greater) in the USA (PO) (Io Therapeutics pipeline, December 2022)
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 28 Feb 2020 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (PO)